Breast Cancer Now media statements
We respond to the Royal College of Radiologists’ clinical radiology and clinical oncology census reports for 2021
In response to today’s Royal College of Radiologists’ clinical radiology and clinical oncology censuses, Baroness Delyth Morgan, Chief Execu...
We respond to research that suggests drugs that neutralise progesterone activity could be a potential risk-reducing treatment for women with altered BRCA genes
In response to research published in Genome Medicine, and part-funded by Breast Cancer Now, which suggests drugs that neutralise progesteron...
We respond to the approval of breast cancer drug abemaciclib for routine use on the NHS
In response to the news abemaciclib has been approved by THE National Institute for Health and Care Excellence (NICE) for routine use on the...
Breast Cancer Now celebrates landmark victory as Trodelvy is recommended for use on the NHS in England
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
Breast Cancer Now welcomes NICE decision to recommend alpelisib with fulvestrant for routine use on the NHS
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to MP Dawn Butler's mission to find the Million Missing Mammograms
Following MP Dawn Butler's appearance on This Morning today, announcing her mission to find the Million Missing Mammograms, Breast Cancer No...
We respond to Macmillan Cancer Support's warning that "almost 50,000 people are still missing a cancer diagnosis in the UK"
Mia Rosenblatt, Associate Director of Policy, Evidence and Influencing at Breast Cancer Now, said:
We respond to a new report from The Institute of Cancer Research, London, into cancer clinical trials
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
We respond to recent announcements around the COVID-19 booster jabs roll-out and share our concerns around potential disruption to breast cancer services caused by Omicron
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to a new study showing how some cancer cells are able to resist PARP inhibitor drugs
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
We respond to NHS England breast cancer waiting times: November 2021
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We welcome the SMC’s approval of two new treatments for use on the NHS in Scotland- trastuzumab deruxtecan (Enhertu) and tucatinib (Tukysa) in combination with trastuzumab and capecitabine
The Scottish Medicines Consortium (SMC) has today announced its decision to recommend two new treatments – trastuzumab deruxtecan (Enhertu) ...